Novo Nordisk's CagriSema Phase III Trial Achieves Glycemic and Weight Loss Goals
Novo Nordisk announced on June 7, 2026, the results of its Phase III clinical trial for CagriSema, a...
Chinese Study: Ecnoglutide Outperforms Semaglutide in Weight Loss by 35%
Sciwind Biosciences announced interim analysis results from its head-to-head study (SLIMMER-UP-SWITC...
Amgen Reports New Results from Evolocumab Trial in the US: 25% Risk Reduction in Primary Endpoint
Amgen announced new overall and subgroup results from the Phase 3 VESALIUS-CV trial of Repatha (evol...
Curium invests €32 million in France to build a prostate cancer radiopharmaceutical production line
Curium, a global leader in nuclear medicine, announced at the "Choose France" summit held in Versail...
German ITM Publishes Single-Scan Individualized Dosimetry Data
ITM Isotope Technologies Munich SE (ITM) presented the latest single-time-point dosimetry data from ...
China's LongBio Pharma lists on HKEX with market cap of HK$10.7 billion
June 5, 2026, Shanghai – LongBio Pharma, an innovative drug developer and a portfolio company of Qim...
Veeva Summit in Denmark Showcases Falcon Platform and Vault AI Plans
At the Veeva R&D and Quality Summit Europe in Copenhagen, Denmark, Veeva Systems showcased its futur...
Rakovina's R&D Spending Rises to 70% of Operating Expenses in Q1
Rakovina Therapeutics Inc. (RKV:TSX.V) reported its first-quarter financial results for the period e...
Altesa ASM Conference Presents Vapendavir Phase 2a Study
Altesa BioSciences announced clinical study results showing that its oral investigational rhinovirus...
Cambridge University Team's AI Universal Vaccine Completes First Human Trial
Researchers at the University of Cambridge have developed a "universal vaccine" using artificial int...